{"id":51183,"date":"2016-12-16T18:37:50","date_gmt":"2016-12-16T18:37:50","guid":{"rendered":"https:\/\/www.nationaldrugscreening.com\/?p=51183"},"modified":"2023-09-06T14:54:45","modified_gmt":"2023-09-06T19:54:45","slug":"operating-a-blended-workplace-dot-vs-nondot","status":"publish","type":"post","link":"https:\/\/www.nationaldrugscreening.com\/blogs\/operating-a-blended-workplace-dot-vs-nondot\/","title":{"rendered":"Operating a Blended Workplace: DOT vs. non-DOT"},"content":{"rendered":"\r\n<p>Our good friend Dee Mason, founder and CEO of\u00a0<a href=\"http:\/\/www.workingpartners.com\/\">Working Partners\u00ae<\/a>, recently wrote an article which was published in the DATIA focus magazine (Fall 2017) edition (DATIA merged with\u00a0<a href=\"https:\/\/ndasa.com\/\" target=\"_blank\" rel=\"noopener\">NDASA<\/a>\u00a0in 2023).\u00a0 The article entitled <em>Operating a Blended Workplace: DOT vs. non-DOT\u00a0<\/em>is an excellent read for many employers with both DOT and non DOT drug &amp; alcohol testing programs.<\/p>\r\n\r\n\r\n\r\n<p>It is important to realize that there are many differences between <a href=\"https:\/\/www.nationaldrugscreening.com\/dot-drug-test\/\"><strong>DOT drug testing<\/strong><\/a> and <strong>non DOT drug testing<\/strong>.\u00a0 Dee does a great job of explaining some of the differences and some of the blended characteristics of an effective drug-free workplace program for employers operating with both DOT and non DOT employees.\u00a0 These employers need a DOT drug free workplace policy and a non DOT drug free workplace policy.<\/p>\r\n\r\n\r\n\r\n<p>Some of the areas discussed where there are significant differences include:<\/p>\r\n\r\n\r\n\r\n<ul>\r\n<li>Accident definition warranting a post-accident test<\/li>\r\n\r\n\r\n\r\n<li>Tested drugs<\/li>\r\n\r\n\r\n\r\n<li>Random testing<\/li>\r\n\r\n\r\n\r\n<li>Definition of safety- sensitive functions\/ positions<\/li>\r\n\r\n\r\n\r\n<li>Reasonable suspicion<\/li>\r\n\r\n\r\n\r\n<li>Testing for new employees<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<p><a href=\"\/wp-content\/uploads\/2020\/07\/datia-focus-operating-a-blended-workplace-dot-vs-11.pdf\">Click Here<\/a>\u00a0to read the full article.<\/p>\r\n\r\n\r\n\r\n<p>Dee Mason is founder and CEO of\u00a0<a href=\"http:\/\/www.workingpartners.com\/\">Working Partners\u00ae<\/a>, a consulting and training firm working with end-user employers and systems to develop and maintain drug-free workplaces. With more than 24 years of experience and servicing 1,700 clients annually,\u00a0<a href=\"http:\/\/www.workingpartners.com\/\">Working Partners\u00ae<\/a>\u00a0crafts policies, trains employees and supervisors, and connects organizations with affordable testing and assistance programs. Dee&#8217;s work includes building drug-free operational systems for large-scale applications including Ohio&#8217;s Bureau of Workers &#8216; Compensation drug-free workplace premium discount program which offered the nation&#8217;s deepest discounts for over 13 years.<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>Our good friend Dee Mason, founder and CEO of\u00a0Working Partners\u00ae, recently wrote an article which was published in the DATIA focus magazine (Fall 2017) edition (DATIA merged with\u00a0NDASA\u00a0in 2023).\u00a0 The article entitled Operating a Blended Workplace: DOT vs. non-DOT\u00a0is an excellent read for many employers with both DOT and non DOT drug &amp; alcohol testing [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":52672,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51183"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=51183"}],"version-history":[{"count":1,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51183\/revisions"}],"predecessor-version":[{"id":118380,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51183\/revisions\/118380"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/52672"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=51183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=51183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=51183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}